Consumers continue to buy risky drugs online that might not contain the correct ingredients and could contain toxic substances.
FDA requests recall of these illegal drug products that contain potentially harmful, undeclared ingredients.
Class I recall issued dues to a possibility that the recalled devices may experience failure or unacceptable delay in analyzing a patients ECG, resulting in possible failure to deliver the appropriate therapy.
Marketing suspension of Trasylol announced, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death.
Changes to prescribing information due to increased risk of first trimester pregnancy loss and increased risk of congenital malformations.
Patient enrollment in the Aprotinin treatment group arm of BART study stopped due to preliminary findings that suggest an increased risk of death associated with aprotinin compared to other antifibrinolytic drugs.
Summary of revisions to the Boxed Warning, Contraindications, Warnings, Precautions, Adverse Reactions sections, and Patient Package Insert/Medication Guide.
Healthcare professionals and consumers informed of the seizure of NC Solution and other drugs for human or animal use, dietary supplements, and ingredients to make those products. NC Solution lacked FDA approval.
Public Health Notification issued describing hazards of using excess cleaning and disinfecting liquids on certain electronic medical equipment. The notification includes recommendations to avoid these hazards.
Postmarketing reports of acute pancreatitis in patients taking Byetta.